Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

A good deal rests on the race to develop a weight-loss pill that will widen the market beyond today's injectable "fat jabs".

Novo Nordisk is teaming up with GoodRx to offer Wegovey and Ozempic for a flat price of $499 a month. Top Air Force general ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a ...

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...

Danish leader will face a challenging landscape among competitors ...